Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach

Katia Mangano, Emanuela Mazzon, Maria Sofia Basile, Roberto Di Marco, Placido Bramanti, Santa Mammana, Maria Cristina Petralia, Paolo Fagone, Ferdinando Nicoletti

Research output: Contribution to journalReview articlepeer-review

Abstract

Macrophage Migration Inhibitory Factor (MIF) is a pro-inflammatory cytokine expressed by a variety of cell types. Although MIF has been primarily studied for its role in the pathogenesis of autoimmune diseases, it has also been shown to promote tumorigenesis and it is over expressed in various malignant tumors. MIF is able to induce angiogenesis, cell cycle progression, and to block apoptosis. As tailored therapeutic approaches for the inhibition of endogenous MIF are being developed, it is important to evaluate the role of MIF in individual neoplastic conditions that may benefit from specific MIF inhibitors. Along with this line, in this paper, we have reviewed the evidence of the involvement of MIF in the etiopathogenesis and progression of glioblastoma and the preclinical data suggesting the possible use of specific MIF inhibition as a potential novel therapeutic strategy for brain tumors.

Original languageEnglish
Pages (from-to)17951-17970
Number of pages20
JournalOncotarget
Volume9
Issue number25
DOIs
Publication statusPublished - Apr 3 2018

Fingerprint Dive into the research topics of 'Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach'. Together they form a unique fingerprint.

Cite this